Literature DB >> 19458559

Sexual dysfunction in middle-aged women: a multicenter Latin American study using the Female Sexual Function Index.

Juan E Blümel1, Peter Chedraui, German Baron, Emma Belzares, Ascanio Bencosme, Andres Calle, Maria T Espinoza, Daniel Flores, Humberto Izaguirre, Patricia Leon-Leon, Selva Lima, Edward Mezones-Holguin, Alvaro Monterrosa, Desire Mostajo, Daysi Navarro, Eliana Ojeda, William Onatra, Monique Royer, Edwin Soto, Soledad Vallejo, Konstantinos Tserotas.   

Abstract

OBJECTIVE: The purpose of this study was to assess the prevalence of sexual dysfunction (SD) and associated risk factors among middle-aged Latin American women using one validated instrument.
METHODS: The Female Sexual Function Index (FSFI) was applied to 7,243 healthy women aged 40 to 59 years who were users of 19 healthcare systems from 11 Latin American countries. An itemized questionnaire containing personal and partner sociodemographic data was also filled out.
RESULTS: Mean +/- SD age of surveyed women was 49.0 +/- 5.7 years, with 11.6 years of schooling on average. There were 55.1% of women who were married, 46.8% who were postmenopausal, 14.1% who used hormonal therapy (HT), and 25.6% who were sexually inactive. Among those who were active (n = 5,391), the mean +/- SD total FSFI score was 25.2 +/- 5.9 and 56.8% of them presented SD (FSFI total score <or=26.55), with a prevalence varying from 21.0% to 98.5% depending on the center. Centers were grouped in terciles (according to mean +/- SD prevalence). The tercile with higher SD prevalence (86.4%) compared with that with lower SD prevalence (32.2%) had significantly older women (49.5 +/- 5.3 vs 48.0 +/- 5.6 y) with a higher rate of vaginal dryness (60.4% vs 40.8%) and older partners (53.0 +/- 6.9 vs 50.2 +/- 7.5 y). Similarly, there was a significantly higher rate of married (68.5% vs 63.1%), postmenopausal (49.7% vs 39.3%), and HT-using women (23% vs 9.2%). There were no differences in regard to their health perception, history of oophorectomy, rape, and partner SD rate (27% vs 26.2%). The total FSFI score was significantly lower in the tercile with higher SD prevalence (22.0 +/- 5.0 vs 27.5 +/- 5.4). Logistic regression analysis was used to determine the odds ratios (95% CIs) for the main risk factors associated with SD among those who were sexually active: bad lubrication, 3.86 (3.37-4.43); use of alternative menopausal therapies, 2.13 (1.60-2.84); partner SD, 1.89 (1.63-2.20); older women (>48 y), 1.84 (1.61-2.09); bladder problems, 1.47 (1.28-1.69); HT use, 1.39 (1.15-1.68); negative perception of female health status, 1.31 (1.05-1.64); and being married, 1.22 (1.07-1.40). Protective factors were higher educational level (women), partner faithfulness, and access to private healthcare.
CONCLUSIONS: The prevalence of SD in this middle-aged Latin American series was found to be high, varying widely in different populations. A decrease in vaginal lubrication was the most important associated risk factor. Differences in the prevalence of risk factors among the studied groups, several of which are modifiable, could explain the variation of SD prevalence observed in this study.

Entities:  

Mesh:

Year:  2009        PMID: 19458559     DOI: 10.1097/gme.0b013e3181a4e317

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  22 in total

1.  Risk factors associated with sexual dysfunction in Brazilian postmenopausal women.

Authors:  K Dombek; E J M Capistrano; A C C Costa; L P F Marinheiro
Journal:  Int J Impot Res       Date:  2016-02-11       Impact factor: 2.896

2.  Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer.

Authors:  P Harter; I Schrof; L M Karl; R Hils; V Kullmann; A Traut; H Scheller; A du Bois
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

Review 3.  Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index.

Authors:  Maria Ida Maiorino; Paolo Chiodini; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito
Journal:  Endocrine       Date:  2015-12-07       Impact factor: 3.633

4.  Sexual dysfunction in patients with polycystic ovary syndrome and its affected domains.

Authors:  Tahereh Eftekhar; Farnaz Sohrabvand; Neda Zabandan; Mamak Shariat; Fedyeh Haghollahi; Akram Ghahghaei-Nezamabadi
Journal:  Iran J Reprod Med       Date:  2014-08

5.  Does Severe Maternal Morbidity Affect Female Sexual Activity and Function? Evidence from a Brazilian Cohort Study.

Authors:  Carla B Andreucci; José G Cecatti; Rodolfo C Pacagnella; Carla Silveira; Mary A Parpinelli; Elton C Ferreira; Carina R Angelini; Juliana P Santos; Dulce M Zanardi; Jamile C Bussadori; Gustavo N Cecchino; Renato T Souza; Maria H Sousa; Maria L Costa
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

6.  Female Sexual Function During the Menopausal Transition in a Group of Iranian Women.

Authors:  Tahereh Eftekhar; Mahboobeh Dashti; Mamak Shariat; Fedyeh Haghollahi; Firoozeh Raisi; Akram Ghahghaei-Nezamabadi
Journal:  J Family Reprod Health       Date:  2016-06

7.  A Mental Health Survey of Different Ethnic and Occupational Groups in Xinjiang, China.

Authors:  Ailing Fu; Bo Liu; Yu Jiang; Junling Zhao; Guanghui Zhang; Jiwen Liu
Journal:  Int J Environ Res Public Health       Date:  2017-01-05       Impact factor: 3.390

8.  Sexual dysfunction in Assyrian/Syrian immigrants and Swedish-born persons with type 2 diabetes.

Authors:  Marina Taloyan; Alexandre Wajngot; Sven-Erik Johansson; Jonas Tovi; Kristina Sundquist
Journal:  BMC Res Notes       Date:  2012-09-24

9.  Female sexual dysfunction in patients with substance-related disorders.

Authors:  Alessandra Diehl; Rosiane Lopes da Silva; Ronaldo Laranjeira
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

10.  Sexual dysfunction prevalence in a group of pre- and postmenopausal Mexican women.

Authors:  Sebastián Carranza-Lira; Flor de Durazno Casillas Núñez
Journal:  Prz Menopauzalny       Date:  2018-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.